Robotic exosuit eliminated gait freezing 5 January, 2024; Gait freezing is one of the most common and debilitating symptoms of Parkinson’s disease, with people suddenly losing the ability to move their feet, often mid-stride, resulting in a series of staccato stutter steps that get shorter until they stop altogether. These episodes are one of the…
Preventing migraine with CGRP
PRODROME trial shows CGRP in migraine prodrome can stop headache and reduce severity 11 December, 2023: Research shows that taking a specific class of migraine medication during the prodromal phase reduces the development and severity of the subsequent headache. In the randomised, placebo-controlled PRODROME trial, treatment with ubrogepant (Ubrelvy) 100 mg, one of the new CGRP…
Evobrutinib in relapsing Multiple sclerosis
Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualised relapse rate for up to 156 weeks compared to oral teriflunomide in both studies In two Phase III trials, evolutionRMS 1 and evolutionRMS 2, the compound known as evobrutinib failed to beat Sanofi’s established Aubagio in reducing MS relapse…
Migraine and obesity
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity 6th December, 2023: Teva Pharmaceuticals has announced that a post hoc analysis [iv] of two Phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY®…
EC approves adult generalised Myasthenia gravis treatment
UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) 4th December, 2023: UCB, a global biopharmaceutical company, today announced that the European Commission (EC) has granted a marketing authorisation for ZILBRYSQ® (zilucoplan) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.1 Zilucoplan is the…
A prodrome for MS?
Study in Neurology evaluated the associations between diseases and symptoms diagnosed in primary care The researchers show that, on a population scale, the frequency of disorders such as depression, constipation, and urinary tract infections is associated with a diagnosis of multiple sclerosis five years later. These results outline a prodromal phase of the disease. Several studies have…
Dravet Syndrome and SCN1A-related epilepsies
New study aims to transform understanding The ‘SCN1A Horizons Natural History Study’ is anticipated to be a milestone in transforming understanding of SCN1A epilepsies, including Dravet Syndrome, one of the most complex and severe developmental and epileptic conditions. The nationwide study aims to define the seizure, neurodevelopmental, and behavioural characteristics of SCN1A-related epilepsies in 400…
Ubrelvy for migraine: positive phase III data
AbbVie recently announced its publication in The Lancet showing that administration of Ubrelvy (ubrogepant) during the prodrome stage of a migraine can reduce the likelihood of a migraine attack developing. Ubrelvy is the first and only acute migraine treatment that has demonstrated Phase III data in the prodrome stage. Christie Wong, Pharma Analyst at GlobalData,…
Digital therapies for tic disorders
NICE are performing a technology assessment to look at digital enabled therapy for tic disorders in children and young people NICE will assess digital therapies for tic disorders in children and young people to determine whether they can be recommended for use in the NHS, based on the available evidence and cost-saving potential. They are…
